EPCAM and neoplasm: It was designed in EpCAM-specific CARs and introduced into human peripheral blood lymphocytes (PBLs); results suggested that EpCAM-specific PBLs significantly inhibit PC-3 tumor cell growth in vitro and in vivo by targeting PCSCs (Figure 4) (152).